▟ Vinebot intrinsic value, daily

← back

SYK Stryker Corporation

healthcare · valued with opus medium conviction · deep-dived 2026-11-16

HOLD
Intrinsic value$162.54
Price (at call)$309.64
Margin of safety -47.5%
vs market (rating basis) -7.2%

Excellent compounder with a robotic moat, but at $310 the market already prices in near-perfect execution.

The story

Stryker is a diversified medtech leader in orthopaedics (with Mako robotics as a growing installed-base moat), MedSurg and neurotechnology. It has compounded revenue at about 11% a year through high-single-digit organic growth plus steady tuck-in acquisitions such as Inari. It is a mature but still growing franchise. Hospital relationships, surgeon training and robotic lock-in support durable pricing and share, and operating leverage keeps lifting margins toward the mid-20s.

Growth, terminal growth, beta and failure risk stay the same; the TTM margin rose to 21.7%, so the target moves only slightly, from 24% to 25%. Sales-to-capital moves from 0.70 to 0.95 because the historical 0.69 is weighed down by acquisition goodwill, while organic growth needs little capital (capex of 0.87B runs below D&A of 1.21B). The horizon moves from 7 to 10 years because the Mako-driven moat looks more durable than I assumed, and my prior value sat more than 100% below a heavily covered price, which told me those two drivers were too harsh.

Value drivers

Revenue growth (Y1)9.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin25.0%
Years to target margin5
Sales-to-capital0.95
Beta0.90
Failure probability1.0%
Cost of capital (WACC)8.7%
Terminal WACC9.1%

Valuation bridge

PV of explicit FCFF27.30B
PV of terminal value47.05B
Equity value61.88B
÷ shares → per share$162.54

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 28.67B 9.0% 22.4% 4.61B 2.49B 2.12B 1.95B
2 31.07B 8.4% 23.0% 5.15B 2.53B 2.62B 2.22B
3 33.49B 7.8% 23.7% 5.71B 2.54B 3.16B 2.46B
4 35.89B 7.2% 24.3% 6.28B 2.53B 3.76B 2.69B
5 38.24B 6.6% 25.0% 6.87B 2.48B 4.40B 2.90B
6 40.51B 5.9% 25.0% 7.28B 2.39B 4.89B 2.97B
7 42.68B 5.3% 25.0% 7.67B 2.27B 5.40B 3.01B
8 44.69B 4.7% 25.0% 8.03B 2.12B 5.91B 3.04B
9 46.53B 4.1% 25.0% 8.36B 1.93B 6.43B 3.04B
10 48.16B 3.5% 25.0% 8.66B 1.71B 6.94B 3.02B

Key risks

  • Acquisition-led growth destroys value if deal premiums keep inflating invested capital
  • Hospital capital budget pressure or reimbursement cuts slow Mako and capital equipment sales
  • Tariffs, supply-chain and pricing pressure stall margin expansion below 25%

Catalysts

  • Mako expansion into spine and shoulder lifting installed base and procedure share
  • Sustained 9%+ organic growth with adjusted operating margin expansion toward 26%

History

DatePriceIntrinsicMoSRating
2026-11-16$309.64 $162.54 -47.5% HOLD
2026-09-25$269.75 $131.91 -51.1% HOLD
2026-08-06$337.03 $144.77 -57.0% HOLD
2026-06-23$310.00 $142.04 -54.2% HOLD